Director John W. Higuchi of Lipocine Inc. (NASDAQ:LPCN) reported a direct purchase of 40,000 shares of the company's common stock on April 7, 2026, according to a Form 4 filing submitted to the Securities and Exchange Commission. The shares were bought at $2.03 each, bringing the total cash outlay to $81,199.
Following the transaction, Higuchi's direct ownership in the firm stands at 203,797 shares. The company carries a market capitalization of $14.4 million. The trade occurred while the share price was trading near a 52-week low of $1.81, after the stock fell roughly 75% over the prior week.
Market commentary included in available analysis suggests the shares may be undervalued at current levels. An InvestingPro note cited the relative strength index as pointing to oversold conditions and referenced additional platform features such as 12 supplemental ProTips and broader financial metrics for subscribers.
Separately, Lipocine disclosed clinical results for LPCN 1154, its investigational treatment for postpartum depression. The company stated that the Phase 3 trial did not achieve the primary endpoint. The study enrolled 90 patients and evaluated change on the Hamilton Depression Rating Scale (HAM-D17); the reduction measured did not reach a statistically significant difference compared with placebo.
Despite the trial outcome on the primary efficacy measure, the company emphasized that LPCN 1154 showed a favorable safety profile in the study. Reported adverse events were characterized as mild to moderate. Lipocine also confirmed that patient visits and enrollment for the Phase 3 trial were completed and that the study was conducted entirely in an outpatient setting.
The trial's continuation was affirmed following a scheduled independent safety review by the Data Safety Monitoring Board, which concluded there were no serious drug-related adverse events. In the wake of enrollment completion and dosing, H.C. Wainwright adjusted its price target for Lipocine to $15 from $7 and maintained a Buy rating.
Taken together, the insider purchase, the clinical readout, and the analyst action represent concurrent developments for Lipocine as the company evaluates LPCN 1154 for postpartum depression treatment. The filing and clinical disclosures provide the principal, documented information available at this time.